Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer

» Alnylam Wins Expanded Heart Drug Approval, Challenging Pfizer

By:
On:
In: Business
With: 0 Comments




Alnylam Pharmaceuticals Inc. won expanded approval for a heart drug that could be the biggest boon yet for the 23-year-old biotech and put it in competition with Pfizer Inc.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *